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Our aim was to test the eﬃcacy of 131-I therapy (RIT) using recombinant human TSH (rhTSH) in patients with diﬀerentiated
thyroidcarcinoma(DTC)inwhomendogenousTSHstimulationwasnotanoptiondue to thepoorpatient’sphysicalconditionor
due to the disease progression during L-thyroxin withdrawal. The study comprised 18 patients, who already have undergone total
ornear-totalthyroidectomy andradioiodineablationand0–12(median5)RITsafterL-thyroxinwithdrawal.Ourpatientsreceived
altogether 44 RITs using rhTSH while onL-thyroxin. Sixto 12 monthsafter the ﬁrst rhTSH-aided RIT, PR and SD was achieved in
3/18 (17%) and 4/18 patients (22%),respectively. In mostpatients (n = 12; 61%) disease progressed despite rhTSH-aided RITs. As
a conclusion,rhTSH-aided RIT proved to add some therapeutic beneﬁt in 39% our patients with metastatic DTC, who otherwise
could not be eﬃciently treated with RIT.
1.Introduction
In thyroidectomized patients with diﬀerentiated thyroid car-
cinoma(DTC),itisbelievedthatserumTSH>30mU/Lopti-
mizes radioiodine trapping and retention and thyroglobulin
(Tg) synthesis by neoplastic cells and is therefore necessary
for reliable serum Tg testing and eﬃcacious radioiodine
therapy [1–4]. Such TSH elevation traditionally has been
achieved by a 4–6-week withdrawal of L-thyroxin (LT4) sup-
pression therapy.
Thyroid hormone withdrawal (THW), however, gener-
ally causes clinical hypothyroidism which is associated with
physical and emotional discomfort, cognitive dysfunction,
and impaired quality of life and ability to work in most
patients. Clinical hypothyroidism is especially poorly toler-
ated by elderly patients with serious concomitant diseases,
to whom it may pose an important health risk [5–8]. In
addition, given its weeks-long duration and the additional
time required for thyroid hormone concentrations to return
to suppressive levels after LT4 therapy is restarted [9, 10],
THW entails a protracted period of serum TSH elevation. In
patientswithmetastases inconﬁned spaces suchas thebrain,
spine, or airways or with a high tumor burden, protracted
TSH elevation sometimes has been documented to stimulate
tumorexpansion orgrowth,causing compressiveorobstruc-
tive symptoms or worsening DTC prognosis [11].
Recombinant human TSH (rhTSH) was developed to
provide TSH stimulation without THW and the morbidity
secondary to clinical hypothyroidism [6, 7]. Because rhTSH
isadministeredinacourseoftwoconsecutivedailyinjections
and because of the relatively short half-life of TSH, rhTSH
use results in TSH elevation lasting only days. In theory,
rhTSH use therefore could decrease the risk of tumor stimu-
lation and its sequelae.
RhTSHhasbeenapprovedsince1998intheUnitedStates
and2000inEuropeasanadjuncttodiagnosticandfollow-up
procedures in patients with DTC [11–15]. In 2005, the drug
was approved in Europe to aid in the administration of large
activities of 131-iodine (131-I) for postsurgical remnant ab-
lation in patients with DTC [16].
RhTSH-aided radioiodine treatment (RIT) of patients
with inoperable locally aggressive or distant metastatic DTC,
is, however, still considered experimental [14, 17]. Although
as of August, 2004 some 216 cases of such RIT had been2 Journal of Thyroid Research
published [14], these reports varied greatly in their level
of detail, particularly with respect to outcome, and only
one published series [18]n u m b e r e dm o r et h a n1 5p a t i e n t s .
Moreover, only a single case of rhTSH-aided RIT of H¨ urthle
cell carcinoma appears to have been published [19].
We sought to test the safety and eﬃcacy of rhTSH as an
alternative to THW in stimulating RIT of patients with ad-
vancedDTC.Therefore, from2002–2007,wegave44rhTSH-
aidedRITs to18 such patients. These patients predominantly
were elderly and had concomitant disease(s), history of
severe hypothyroid or compressive symptoms or evidence of
tumor progression during THW, or both, which precluded
THW. Of note, based upon our data suggesting that RIT may
be eﬀective in patientswith histologically conﬁrmed H¨ urthle
cell carcinoma [20, 21], our series included six such patients.
We now report on our initial experience with rhTSH-aided
RIT.
2.PatientsandMethods
2.1. Patients and Ethical Considerations. The present series
c o m p r i s e s1 8p a t i e n t s( 1 2f e m a l e s ,6m a l e s )w h or e c e i v e d
rhTSH-aided RIT for histologically conﬁrmed, advanced
recurrent or residual DTC at our tertiary referral clinic, the
Institute of Oncology, Ljubljana, Slovenia from January 2002
through September 2007. The patients were followed for a
median, 50 months (range, 15–99 months) after rhTSH-
aided RIT. Earlier, more limited data on patients number 2,
3, 4 and 6 have been published elsewhere [20].
Table 1 includes patient characteristics for the series. The
median age was 72 years (range, 37–83 years) and 13 (72%)
patients were over 65. Five (28%) patients had papillary
carcinoma, of whom two had the follicular variant and one
had poorly diﬀerentiated tumor, seven (39%) had follicular
carcinoma, of whom one had the insular variant, and one
poorly diﬀerentiated tumor, and six (33%) patients had
H¨ urthle cell carcinoma.
The primary diagnosis was established from 1993–2003.
At the initial presentation at our clinic (“presentation”), pT
stage [22] according to the tumor node metastasis classiﬁca-
tion [16] was pT4 in 12 patients (67%), pT3 in ﬁve patients
(28%) and pT2 in one patient (5%). N stage was N0 in 14
(83%) patients, and N1 in three patients (17%). Distant
metastases were evident at presentation in eight (44%)
patients. At the time of the ﬁrst rhTSH-aided RIT, the
metastatic site was lungs in ﬁve patients (27.5%), bone +
lungs in four patients (22%), only bone in three patients
(16.5%), mediastinum in two patients (11%), bone + brain,
bone + liver, bone + mediastinum, and lung + kidney were
metastatic sites in one patient (5.5%). In two patients (11%)
distant metastases were found as well as regional recurrent
tumor which was not surgically treated (one was inoperable,
while in the other patient numerous metastatic sites were
present).
All patients had total or near-total thyroidectomy, and all
but one had previous RIT (median: 5 treatments, range: 1–
12 treatments after THW, with cumulative activities ranging
from 3.6 to 68.33GBq (median 27.89GBq) as shown on
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Figure 1:Cumulative radioiodineactivity per patient by TSHstim-
ulation method.
Figure 1. The time from the most recent prior THW-aided
RIT to referral for rhTSH-aided RIT ranged from 2.5 to 84
months (median: 12 months). Twelve (67%) patients had
undergone external beam radiotherapy (EBR) within 1–120
months (median: 6.5 months) before referral (another three
patients after the ﬁrst rhTSH-aided RIT), while eight (44%)
had chemotherapy with either adriamycin or vinblastine
from within one week to 120 months (median: 6 months)
before referral.
Speciﬁc indications for rhTSH were generally multiple,
including one or more of (A) concomitant disease (n = 5)
or (B) metastasis-related neurological symptomatology (n =
9) that posed a danger of important exacerbation under
hypothyroid conditions or (C) a history of severe symptoms,
evidence of tumor progression, for example, an immense
increaseinserumTg,orbothduringhypothyroidism(n = 4)
or (D) frailty due to advanced age (n = 10). Our main aim
in giving rhTSH, however, was to avoid the risk of tumor
progression with concomitant symptoms, related to that.
The study was approved by our center’s Institutional Re-
view Board and Ethics Committee and performed in accor-
dance with the ethical standards of the World medical asso-
ciation declaration of Helsinki. Written informed consent
was obtained from every patient before each rhTSH-aided
RIT.
2.2. RhTSH-Aided RIT and Follow-Up Protocol. Figure 2
illustrates our rhTSH-aided RIT and follow-up protocol.
For each RIT, patients received an intramuscular injection
of 0.9mg rhTSH (Thyrogen, Genzyme Corporation, Cam-
bridge, Mass, USA) on two consecutive days, followed on
the third day by the oral administration of a capsule of 5.5–
7.4GBq of 131-I. RIT activities were determined empirically,
according to the same standard institutional criteria as for
activities after THW. No adjustment was made in the RITJournal of Thyroid Research 3
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3.7–7.4 131-I GBq and
Figure 2: Protocol for rhTSH-aided radioiodine treatment and fol-
low-up.
activity to oﬀset the faster renal clearance when patients
are euthyroid [23]. Dosimetry of metastases was not done
because it is not routinely performed at our department.
Decision when to give multiple rhTSH-aided RITs was
tailored individually. We stopped with rhTSH-aided RITs at
cumulative dose of approximately 37GBq, although some of
the patients were heavily pretreated or when rhTSH-aided
RITs proved ineﬀective.
In all patients, a low-iodine diet was prescribed for ap-
proximately two weeks preceding the radioiodine adminis-
tration, and at the time of that administration, dietary or
therapeutic iodine contamination was ruled out based on
thorough history. Urinary iodine testing was not performed.
Patients with clinically suspected or documented brain,
skull, or vertebral metastases (n = 10) received steroid
prophylaxis against peritumor edema and related neurolog-
ical symptoms. The steroid regimen was oral methylpred-
nisolone, from 16 to 48mg/day, for at least 5 days, starting
the day of the ﬁrst rhTSH injection. This regimen was based
on our Institute’s routine scheme for patients with brain or
spinal cord metastases or both undergoing EBR, and was
tailored to each patient’s clinical situation [17, 24].
All patients received suppressive L-thyroxin (LT4), that
is, the individualized dose, ranging from 1.5–2.5mcg/kg of
body weight, necessary to achieve serum TSH < 0.1mU/L,
throughout the study. In conformity with the Slovenian
Radiation Protection Law, patients were hospitalized in the
radionuclide therapy ward with full radiation protection
from the day of radioiodine administration to the day the
radiation dose rate at one meter reached <32microSv/h.
Adverse eﬀects were evaluated through careful observa-
tion by specially trained radiation ward medical personnel,
physical examination, thorough history and spontaneous
patient report.
2.3.AssessmentofRadioiodine UptakeandOutcomeofrhTSH-
Aided RIT. Radioiodine uptake was assessed by postthera-
peuticWBS (rxWBS)and when indicated, by “spotimaging”
of regions of interest, performed on the 3rd to 6th day after
radioiodine administration, using a dual-headed gamma
camera (Elscint, Haifa, Israel) equipped with parallel-hole,
high-energy collimators. rxWBS was taken over approxi-
mately 15 minutes, with a camera velocity of 18–20cm/min.
At least 600KCnts were acquired per “spot image”.
In this patient group, follow-up visits were scheduled
every 6–12 months, in some cases less, taking into account
the clinical status and progression risk and always comprised
measurement of serum Tg, TSH, thyroid hormone and anti-
Tg antibody levels. Two patients also received rhTSH-aided
follow-up diagnostic WBS (dxWBS), which was acquired
over at least 35 minutes, with a camera velocity of 6–
8cm/min. All WBS were interpreted by experienced nuclear
medicine physicians.
The eﬃcacy and outcome of initial rhTSH-aided RIT
were assessed via a within-patient comparison of the num-
ber, location, and extent of 131-I-avid lesions on the rhTSH-
aidedrxWBSversusonthemost recentavailableTHW-aided
rxWBS. For the second and subsequent rhTSH-aided RITs,
the rhTSH-aided rxWBS was compared with the most recent
prior rhTSH-aided rxWBS. At each follow-up visit a detailed
history,clinicalstatus,laboratorytests,neckultrasonography
andchestand/orboneradiographywereobtained.Whenever
because of tumor progression or suspicion of complications
other treatment options (surgery or radiotherapy) were
considered, also computed tomography, magnetic resonance
imaging (MRI), or both were performed. In none of our
patients PET-CT was performed. The overall outcome of the
rhTSH-aided RIT(s) was assessed based on the comparison
of clinical and radiological ﬁndings and serum Tg levels
before the ﬁrst rhTSH-aided RITversus after the most recent
rhTSH-aided RIT. All comparisons were unblinded.
Outcome categories were deﬁned as deﬁned by Jarzab
et al. [18].
(i) Complete response (CR): no pathologic uptake on WBS
andfulltumorremissiononradiologicalexamination,serum
Tg level <1mcg/L on LT4 therapy or <2microg/L after
rhTSH stimulation or THW;
(ii) Partial response (PR): >25% decrease in tumor size and/
or in serum Tg level if there was no increase in tumor size;
(iii) Stable disease (SD): ≤25% decrease to 25% increase in
t u m o rs i z ea n d / o rs e r u mT gl e v e l ;
(iv) Progressive disease (PD): >25% increase in tumor size
and/orinserumTgleveland/ornew131-I-avidfocionWBS.
2.4. Biochemical Evaluation. To conﬁrm adequate TSH
suppression and rule out LT4 over dosage and to permitJournal of Thyroid Research 7
(a) (b) (c)
Figure 3: Treatment of a 73-year-old patient with H¨ urthle cell carcinoma. (a) rxWBS taken 48 hrs after the ﬁrst application of 5.5GBq of
131-ITHW-aided RIT in 1997:pathologicuptake is visible in the thyroid bed, in the 4th thoracicvertebra (Th4),andin thelungs bilaterally.
(b) An rxWBS (following a ﬁfth RIT after hormone withdrawal with 7.4GBq of 131-I in 2001) shows regression of metastatic disease:
pathologic uptake in the lungs is no longer visible; the foci of uptake in Th4 appear to be smaller and less intense; cumulative uptake of RAI
is 2%. (c) An rxWBS (followinga second rhTSH-aided RIT with 7.4GBq of131-I in 2002) shows regression of metastaticdisease: the fociof
uptake in Th4 appear to be smaller and less intense; cumulative uptake of RAI is 0.05%.
t h ea c c u r a t eu s eo fs e r u mT ga sat u m o rm a r k e r ,T S H ,f r e e
LT4, free triiodothyronine (FT3), Tg, and anti-Tg-antibody
(TgAb) values were determined before the ﬁrst rhTSH
injection,beforetheﬁrst injection in eachsubsequentrhTSH
course, and 24hr after the second injection in each rhTSH
course. Eﬀect of rhTSH RIT on Tg concentration was deter-
mined by comparison of Tg concentration before the ﬁrst
rhTSH injection of each RIT and two months thereafter.
Serum TSH, FT3, free LT4, and Tg were measured using
commercially available kits (LIAISON, DiaSorin, Saluggia,
Italy). The serum TSH and Tg measurements were carried
out by two-site immunoluminometric assay.
2.5. Statistical Methods. For this observational, open-label,
nonrandomized study, only descriptive statistics were gener-
ated, with one exception. We used the Student’s t-test, per-
formed on Microsoft Oﬃce Excell 2003 to compare serum
TSH levels after the ﬁrst rhTSH course versus after the most
recent THW for which data were available.
3.Results
3.1. Treatments. Our 18 patients received a total of 44
r h T S H - a i d e dR I T s :ﬁ v ep a t i e n t sr e c e i v e do n e ,s i xh a d2 ,t w o
patients had 3, four had 4, and one patient had 5 rhTSH-
aided RITs. The median time between rhTSH-aided RITs
w a s1 0m o n t h s( r a n g ef r o m6t o2 2 ) . T h ea v e r a g ec u m u -
lative rhTSH-aided RIT activity was 15.77GBq (median:
13.75GBq, range, 5.22 to 34.52GBq).
3.2. Radioiodine Uptake. At referral for the 1st rhTSH-
aided RIT all patients had proven functional cancer foci,
conﬁrmed by visible radioiodine uptake on the most recent
THW-aided rxWBS (n = 18) or dxWBS (n = 2). In all
patients,everyrxWBSwas positive,showing at leastone131-
I-avid lesion; altogether 60 iodine-avid foci were detected in
the 44rxWBS.
3.3.TgResponse, OutcomeofRhTSH-Aided RIT, and Survival.
The most prominent change from basal Tg value to the 2nd
month check-up Tg value was seen in patient 1 (91%), The
highest rise from baseline Tg value was seen in patient 4
(3593%).ChangesofTglevelsfromuptoatleast6monthsin
all patients were consistent with the results of post-RIT WBS
and the other follow-up imaging modalities.
No CR was observed. A PR was achieved in three (17%)
patients (nos. 1, 2, 9), in whom serum Tg after initial pro-
gressive rise in Tg level at ﬁrst rhTSH-aided RIT decreased
24% (minimally) and 87% (maximally) from pre-rh TSH-
aided RIT level at last checkup after 2 and 6 months after
last rhTSH-aided RIT. One of these three patients (patient
#2) had a long-lasting response to RIT after hormone
withdrawal and rhTSH-aided RIT. In this individual, a 73-
year-old female with H¨ urthle cell carcinoma, serum Tg
decreased by 35% at the ﬁrst checkup at two months after
the ﬁrst rhTSH-aided RIT and by another 24% at the
check-up at two months after the second rhTSH-aided RIT.
Thyroid carcinoma remained stable for 81 months and she
died because of causes not related to thyroid carcinoma.
Scintigraphically and radiographically, this patient showed
a complete regression of the 131-I-avid metastases in both
lungs and a stabilization of the metastatic disease in the
thoracic vertebra (Figure 3).
A SD was achieved in four (22%) patients (nos. 13, 14,
17 and 18), in whom serum Tg values changed from 24%
decrease to 23% increase. The smallest change was observed
in patient 17, where after 13% increase after ﬁrst rh TSH-
aided RIT steady plateau of approximately 10% decrease was
observed.8 Journal of Thyroid Research
(a) (b) (c)
Figure 4: A 58-year-old patient with papillary thyroid carcinoma and poorly diﬀerentiated carcinoma. (a) An rxWBS taken 48 hrs after
application of 5.5GBq of 131-I under THW, in 2004: pathologic uptake is seen in the mid-thoracic vertebrae, throughout the right
hemithorax, in 2 foci in the anterior left hemithorax, and in the lower lumbar vertebrae. (b) One year later: an rxWBS taken 48 hours
after an rhTSH-aided RIT with 5.5GBq of 131-I in the same patient, demonstrates progressive disease despite a total 9 of RITs (3 rhTSH-
aided) with a cumulative activity of 49.6GBq, EBR, and chemotherapy: pathologic uptake in the thoracic and lumbar vertebrae, as well as
the bilateral pathologic accumulation in the thorax are larger and more intense, new foci of pathological uptake are seen in the right side
of the neck, in the third lumbar vertebra, and faintly in the left pelvis. (c) A bone scan of the same patient, performed 4 months after the
last rhTSH-aided 131-I treatment: osteolytic lesions are clearly visible in the left sacroiliac joint, and in the Th6–Th8 and L3–L5 vertebral
segments. Additionally, faint osteolytic lesions may be suspected in the 5th right rib anteriorly and in the L1 and S1 vertebra.
In most patients (n = 11, 61%) disease progressed (DP)
despite rhTSH-aided RITs. The highest increase in Tg values
was seen in patient 4, where the last Tg value at the last 6
month checkup after the last rhTSH-aided RIT increased for
approximately 3500% compared to the value at the 2 month
checkup after the last rhTSH-aided RIT despite occasional
drop in Tg values at preceding rhTSH-aided RITs.
With a median 50 months of follow-up, six (33%)
patients were alive. Nine (50%) patients died during follow-
up because of distant metastasis 15, 16, 24, 27, 28, 33, 46,
54 and 65 (median 28) months after the ﬁrst rhTSH-aided
RIT. Three patients died of causes not related to thyroid
cancer.
3.4. Other Biochemical Eﬀects of RhTSH. Serum TSH levels
after the second rhTSH injection were 58–>10000mU/L
(median, 135mU/L). Following the rhTSH injections most
patients had stable normal serum FT3 and normal to slightly
elevated free FT4.
3.5. Side Eﬀects of RhTSH-Aided RIT. RhTSH was in all but
one patient generally well tolerated, with transient (up to
ﬁ v ed a y s )a n dm o s t l ym i l ds i d ee ﬀects: nausea in nine (50%)
patients, headache in six (33%) patients, slight to moderate
escalation in bone metastasis pain that was manageable
with nonopioid medication in three patients, a “ﬂu-like
syndrome” or muscle cramps in two patients, and sweating
in one individual.
Only one patient (no. 16)experienced serious side eﬀects
of rhTSH. This 58-year-old male with poorly diﬀerenti-
ated papillary histology and metastases in the lungs, ribs,
thoracic, and lumbar vertebrae and pelvis (Figure 4), had
been heav-ily pretreated (6 THW-aided RITs with a cumu-
lative 131-I activity of 32.93GBq, EBR, and chemotherapy).
The patient received steroid prophylaxis with methylpred-
nisolone 56mg/day.After the ﬁrst injection of his 2nd course
of rhTSH, he developed severe vomiting, which subsided
after a larger dose of methylprednisolone (120mg/day). He
also suﬀered severe pain in his known bone metastatic
sites, that despite high-dose steroid therapy escalated after
the second rhTSH injection to become manageable only
by opioid medication. Three days after the second rhTSH
injection (i.e., 2 days after administration of 7.2GBq of
radioiodine), a spastic paraparesis occurred. Despite anti-
edematous therapy with 10% mannitol, furosemide, and
continued high-dose steroids, the paraparesis progressed
within hours to a complete spastic paraplegia due to a
pathological 7th thoracic vertebra fracture and spinal cord
compression that were conﬁrmed by an MRI. The para-
plegia required immediate surgical decompression, which
was feasible, since the patient’s radiation dose rate was
already below the regulatory limit. At the time of surgical
procedure the radiation dose rate of this patient was below
32microSv/hour. None of the surgical team personnel or
nursing staﬀ which took care of this patient during or after
surgical procedure reached the monthly or annual receivable
dose (regulatory limit in Slovenia is 20mSV/year). We did
not expect such a detrimental course, especially for the ﬁrst
rhTSH-aided RIT ended well. It is possible that neurological
symptoms were triggered by rhTSH-aided RIT.
In another patient with a previously known supraven-
tricular tachycardia, an episode of atrial ﬁbrillation with
rapid ventricular response was noted after the second rhTSH
injection of the third course of rhTSH, most likely causedJournal of Thyroid Research 9
by accompanying fever due to rhTSH injection and was not
accompanied by thyrotoxicosis. The patient in question also
suﬀered a ﬂu-like syndrome due to rhTSH injection and
a headache, for laboratory parametra excluded infectious
cause of a fever. Fibrillation lasted for a day and came to
an end after antipyretic therapy was started. This adverse
eﬀectofmoderate grade wasobserved beforethe radioiodine
administration on day three, which caused no change in the
intensity of the adverse events.
4.Discussion
Our group of patients given rhTSH-aided RIT for metastatic
DTC represents, to our knowledge, the second largest such
p u b l i s h e ds e r i e sf o rw h o mo u t c o m e so ft h i sm o d a l i t yh a v e
been reported. Our patients had a variety of unfavorable
prognostic characteristics—72% were over65 and 61%, over
70 years old, all had distant metastases, 56% in the bone,
half of whom also had soft tissue metastases, and 50% had
H¨ urthle cell or poorly diﬀerentiated papillary or follicular
histology. Explaining the general frailty of our series, our
most important inclusion criterion was inability to undergo
THW, because of one or more of advanced age, serious
concomitant illness, late-stage DTC, or history of severe
hypothyroid symptoms or of tumor progression during
THW. Beyond this, our patients were heavily pretreated,
94%having receivedTHW-aidedRIT(median,5treatments,
mean cumulative activity, 27.89 GBq), 67%, EBR, and 44%,
chemotherapy.
Despite the “unfavorable proﬁle” of our patient popula-
tion, seven (39%) of our 18 patients had results suggesting
some therapeutic beneﬁt of rhTSH-aided RIT, ranging from
transient disease stabilization during rhTSH-aided RITs,
disease progression after ﬁrst few rhTSH-aided RITs with
a sudden drop to a PR, and improvement after each
rhTSH-aided RITs with disease progression between them,
that included regression of lung and reduction of bone
metastases. In a period of PR and SD, most of the patients
had less problems related to DTC compared to period of
PD. However, unsurprisingly given the characteristics of our
series, 61% of our patients had PD despite one or more
rhTSH-aided RITs, and 66% died during the follow-up, nine
(50%) because of progression of distant metastases.
Compared to other published series [8, 17–19, 25–27],
our clinical beneﬁt rate (39%) falls into the low end (40%–
73%), and our mortality rate probably because of long
follow-up period, into the high end of the spectrum (0%–
33%). However, our patient population appears to have
been older, to have included a higher proportion of patients
with bone metastases, unfavorable histology, or both, and
to have been more heavily pretreated than most of the
otherpublishedseries.Moreover,comparisonsmustbemade
with caution because of the small numbers of most series
and disparate response criteria and length of follow-up in
diﬀerent studies.
Notwithstanding the advanced age, frailty, and heavy
tumor burden of our patients, rhTSH was well tolerated, but
one of our patients had serios side eﬀects (no. 16). Despite
steroid prophylaxis, very shortly after his rhTSH injections,
he suﬀered severe bone pain escalation and vomiting and a
pathological fracture of the 7th thoracic vertebra with spinal
cord compression resulting in spastic paraplegia requiring
immediate surgical decompression. This case was similar to
isolated cases reported elsewhere [12–19]. The patient’s lack
of response to high-dose steroid prophylaxis and treatment
and documented rapid tumor growth after previous THW-
aided RIT suggest that this adverse event might have been
the consequence not just of tumor edema, but growth after
rhTSH. However, another patient in our series (no. 13) with
similar disease characteristics and premedication had no
clinical evidence of tumor expansion after three courses of
rhTSH and achieved at least transient disease stabilization.
Moreover, none of our patients with neck, mediastinal, or
pulmonary metastases experienced dyspnea or a choking
feeling that could be associated with tumor edema, and six
of ten patients with bone metastases reported no, and three
of ten only mild escalation of skeletal pain after rhTSH, less
intensityanddurationthanexperiencedwithpreviousTHW.
Therefore we share the opinion [25]t h a te v e ni np a t i e n t s
with known or suspected metastases in conﬁned spaces,
rhTSH applicationforRITusuallydoesnotpresentanotable
risk if special caution and steroid coverage are employed.
The present study conﬁrms and extends our earlier
ﬁndings [20, 28] that patients with histologically conﬁrmed
H¨ urthle cell carcinoma frequently exhibit uptake and some-
timesderiveclinicalbeneﬁt,fromlargeradioiodineactivities.
Numerous 131-I-avid lesions were detected in ﬁve of six of
our patients with such histology, and our patient with the
longest and most radiologically extensive response belonged
to this subgroup. The only other previously published
H¨ urthle cell carcinoma patient given rhTSH-aided RIT also
had radioiodine uptake on his posttherapy scan, but appears
not to have responded to this treatment [19].
Our study had several important limitations. First, its
design was observational and prospective only for the
rhTSH-aidedRITcomponentofthepatients’overalltherapy,
and follow-up was relatively short. In addition, all compar-
isons and observations were unblinded. Second, since we did
not conduct dosimetry or empirically adjust the radioiodine
activity for the faster 131-I clearance under euthyroid
conditions [23] we may have used a suboptimal radioiodine
activity. Our reasons for omitting dosimetry included the
well-known limitations of this maneuver [11, 29], the wish
to spare frail patients an additional procedure, and the
additional cost of rhTSH for this procedure. Moreover, we
note that to our knowledge only one published study [20]
adjusted the radioiodine activity for rhTSH versus THW.
Another limitation is that the heterogeneity in the
number of courses and cumulative activities of rhTSH-aided
RIT, and particularly in the amount and recent prior THW-
aided RIT,EBR,and chemotherapy, makeit diﬃculttogauge
the degree to which the PRs or disease stabilizations are
attributable solely to rhTSH-aided RIT. For example, all but
two of the six patients with clinical beneﬁt from rhTSH-
aided RIT had EBR with or without chemotherapy within
1–3 months before the ﬁrst rhTSH-aided RIT. However,
the clinical beneﬁt would appear to be attributable mainly10 Journal of Thyroid Research
or solely to rhTSH-aided RIT in our long-standing partial
responder (patient 2) and in one patient with SD (no. 17),
who had long intervals (27 and 9 months, respectively, since
prior therapy.
An open issue is whether to continue RIT in heavily
treated patients with aggressive but functional metastases,
in whom the modality achieves only transient disease stabi-
lization. In our institution we present each such patient to a
team of doctors, who take part in treating thyroid carcinoma
patients (including surgeons, who are pro-rhTSH-aided RIT,
mostly because they believe it is last possible treatment),
and the decision whether to continue with rhTSH-aided
RITs depend on the decision of the team mentioned. Mostly
we try to continue with rhTSH-aided RITS as long as
posible, despite the pretreatment with RIT, as long as
there is the smallest possibility of success. Sometimes the
disease stabilization means important clinical palliation.
Consideration should be given to enrolling such patients in
clinical trials of molecular approaches, when feasible.
Recently, additional outcome data from the Institute
Goustave-Roussy (IGR), Villjuif, France, suggests that in
the distant metastatic DTC setting, RIT is most eﬀective in
younger patients with small, functional soft tissue lesions
[30]. These data also suggest that >95%of CRsto RITcan be
attained by fractionated administration of up to 27GBq of
131-I. Data of our and other studies [7, 17, 19, 20, 25, 27, 29,
30] prove that rhTSH-aided RIT in the late-stage metastatic
DTC is safe and may be eﬀective. RhTSH-aided RIT improve
patient quality of life and ability to work [4–6, 14]a n d
decrease radiation exposure in extrathyroidal compartments
[16].AcomparativetrialofrhTSHversusTHWasanadjunct
to RIT may be highly clinically relevant, and feasible, in these
earlier-stage patients.
In conclusion,useofrhTSHoﬀersthepossibility ofhigh-
dose RIT to patients with metastatic DTC who otherwise
would be unable to receive such treatment due to the risk
of intolerable or serious adverse reactions to the clinical
hypothyroidism of THW. RhTSH-aided RIT has minimal
side eﬀects in most patients and oﬀers therapeutic beneﬁt
even in some patients with late-stage DTC.
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